Charting the Future of Canadian Adult Acute Myeloid Leukemia (AML) Laboratory Testing: A Canadian Leukemia Study Group Current State Mapping of Diagnostic AML Laboratory Practice
Cross-sectional survey reveals diagnostic biomarker variation and turnaround time priorities in hematology laboratories, indicating widespread demand for standardized national guidelines.
Key Points
To characterize the current landscape of diagnostic testing, reporting practices, and turnaround time targets for adult acute myeloid leukemia across Canadian laboratories.
Administered a cross-sectional online survey in September 2024 to laboratory hematology leadership (N = 18) representing 16 laboratories across 10 Canadian provinces.
Turnaround time (TAT) targets were predominantly set via internal consensus (62%) or external guidelines (44%), with TAT reduction marked as a top priority by 56% of laboratories.
Rapid testing (5-day TAT) was frequently available for FLT3-ITD (69%), FLT3-TKD (56%), and NPM1 (56%), but was limited for IDH1 and TP53.
Respondents expressed strong interest in shared measurable residual disease assay validation (56%) and unanimous support for establishing national laboratory consensus guidelines.